About NeuroGT
NeuroGT is a Healthcare company based in United States founded in 2019 by Haiyan Fu. Its chief executive, as recorded, is Rich Giersch. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative.
Company details
Developer of gene therapies for rare neurogenetic diseases. It focuses on lysosomal storage disorders and other conditions affecting the central nervous system. The company utilizes advanced gene therapy technologies, including AAV gene replacement therapy and antibody cleaver technology, to target the root causes of these diseases. A key aspect of its approach is a commitment to precision and patient-centric care. Development also includes a scale-up AAV manufacturing platform to support internal development and external partnerships.
- Headquarters Research Triangle Park, United States
- Founders Haiyan Fu
- SectorsHealthcare
- Email••••••••
- Website neurogt.com
- Social LinkedIn
- Latest Funding Round$456.41K (USD), Grant
Sep 2024
- Investors
Funding Insights of NeuroGT
- Total Rounds 4
- Last Round Grant — $456,414
- First Round $679,426
(Apr 2020)
- Investors Count 1
All 4 funding rounds of NeuroGT with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
1 investors in total: 1 institutional.
Investors in NeuroGT
NeuroGT has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for NeuroGT
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NeuroGT
2 people are tracked at NeuroGT (2 in leadership).
| Name | Role | Group |
|---|---|---|
Haiyan Fu | Founder | Leadership |
Rich Giersch | CEO | Leadership |
Complete people profiles for NeuroGT
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NeuroGT
3 dated milestones of NeuroGT across 5 years, from founding to its latest funding, stage changes and deals.
- Founded NeuroGT is founded.
- Funding First funding round of $679K.
- Funding Latest funding round, Grant, of $456K.
Web traffic of NeuroGT
The website of NeuroGT (neurogt.com) receives about 1K visits a month.
- Monthly visits1K
▼ 21.4% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NeuroGT (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NeuroGT
NeuroGT was founded in 2019 and raised its 1st funding round 1 year after it was founded.
NeuroGT is headquartered in United States. It is registered at North Carolina, United States.
Rich Giersch is the CEO of NeuroGT, as recorded in our data.
Developer of gene therapies for rare neurogenetic diseases. It focuses on lysosomal storage disorders and other conditions affecting the central nervous system. The company utilizes advanced gene therapy technologies, including AAV gene replacement therapy and antibody cleaver technology, to target the root causes of these diseases. A key aspect of its approach is a commitment to precision and patient-centric care. Development also includes a scale-up AAV manufacturing platform to support internal development and external partnerships.
NeuroGT has 1 investor. Key investors include HHS.